
Tumor PDO 2.0
An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.
Models & products
Compare tumor PDOs, normal-tissue organoids and disease models by project goal, available assays and collaboration format. Browse options for supplied models, TRiCBIO-run studies and custom development.
Start from a common study combination or select up to three models.
Choosing PDO 1.0 or PDO 2.0Featured models · use the filters to explore the full portfolio
0 of 3 models selected for comparison

An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.

Assess drug-related kidney injury using morphology, nephron markers and molecular readouts; the culture approach is selected by compound mechanism and priority endpoint.

Human lung organoids for pulmonary-injury and candidate studies, combining airway and alveolar cell profiling with changes in tissue morphology.

Organoids from adjacent non-tumor liver tissue for epithelial-biology, drug-exposure and tumor-versus-adjacent-tissue studies.

Study gastric epithelial biology and drug exposure in normal human organoids, with imaging of tissue structure, proliferation and mucin-related markers.

Track morphology and marker expression from primary establishment and passaging through proliferative, secretory and receptive stages, with epithelial-identity profiling throughout.

Human fallopian tube organoids with serial culture morphology and source-tissue/organoid H&E comparison, plus study-specific identity and functional assays.

For inflammatory bowel disease (IBD), established inflammation and barrier assays in mouse intestinal organoids support candidate comparison across morphology, permeability, viability and F-actin/ZO-1; we tailor a human study to the sample and program goal.

Patient-derived breast tumor organoids for single-agent and combination studies, with PDO 2.0 / ALI considered when immune context is relevant.
Explore disease and barrier models, filter by organ, study goal or collaboration format, or discuss a tailored program for specialized tissues and functional endpoints.
PRODUCT CATALOG

A starter kit for PDO 2.0 / ALI recovery and initial culture, with protocol guidance and technical support.

Core reagents for teams with ALI experience or preparing to establish a routine PDO 2.0 culture workflow.

For primary sample processing, organoid establishment, expansion and passaging, with gentle dissociation and workflow guidance matched to the sample.

For organoid cryopreservation and post-thaw recovery, supporting model storage and biobanking.

For TME-associated cell profiling by flow cytometry or immunofluorescence, with antibody panels matched to the model and assay platform.
Models & products
Compare tumor PDOs, normal-tissue organoids and disease models by project goal, available assays and collaboration format. Browse options for supplied models, TRiCBIO-run studies and custom development.
Start from a common study combination or select up to three models.
Choosing PDO 1.0 or PDO 2.0Featured models · use the filters to explore the full portfolio
0 of 3 models selected for comparison

An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.

Assess drug-related kidney injury using morphology, nephron markers and molecular readouts; the culture approach is selected by compound mechanism and priority endpoint.

Human lung organoids for pulmonary-injury and candidate studies, combining airway and alveolar cell profiling with changes in tissue morphology.

Organoids from adjacent non-tumor liver tissue for epithelial-biology, drug-exposure and tumor-versus-adjacent-tissue studies.

Study gastric epithelial biology and drug exposure in normal human organoids, with imaging of tissue structure, proliferation and mucin-related markers.

Track morphology and marker expression from primary establishment and passaging through proliferative, secretory and receptive stages, with epithelial-identity profiling throughout.

Human fallopian tube organoids with serial culture morphology and source-tissue/organoid H&E comparison, plus study-specific identity and functional assays.

For inflammatory bowel disease (IBD), established inflammation and barrier assays in mouse intestinal organoids support candidate comparison across morphology, permeability, viability and F-actin/ZO-1; we tailor a human study to the sample and program goal.

Patient-derived breast tumor organoids for single-agent and combination studies, with PDO 2.0 / ALI considered when immune context is relevant.
Explore disease and barrier models, filter by organ, study goal or collaboration format, or discuss a tailored program for specialized tissues and functional endpoints.
PRODUCT CATALOG

A starter kit for PDO 2.0 / ALI recovery and initial culture, with protocol guidance and technical support.

Core reagents for teams with ALI experience or preparing to establish a routine PDO 2.0 culture workflow.

For primary sample processing, organoid establishment, expansion and passaging, with gentle dissociation and workflow guidance matched to the sample.

For organoid cryopreservation and post-thaw recovery, supporting model storage and biobanking.

For TME-associated cell profiling by flow cytometry or immunofluorescence, with antibody panels matched to the model and assay platform.